MedTrace Logo

Atorvastatin Effect on Reduction of COPD Exacerbations

NCT04789057 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2026-04-21

No results posted yet for this study

Summary

It is a randomized, multicenter, prospective, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 12 Hospital Pulmonary Departments to evaluate the effectiveness of atorvastatin on the reduction of inflammation process in patients with chronic obstructive pulmonary diseases, and possible biomarkers for personalized treatment of COPD.

Conditions

  • Copd
  • COPD Exacerbation
  • Smoking
  • Gene Expression
  • Atorvastatin

Interventions

DRUG

Atorvastatin 40 Mg Oral Tablet

p.o., once daily

DRUG

Placebo

p.o., once daily

Sponsors & Collaborators

  • Medical Research Agency, Poland

    collaborator OTHER_GOV

  • Medical University of Bialystok

    lead OTHER

Principal Investigators

  • Robert Mróz, Prof. MD · Medical University of Bialystok

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-11
Primary Completion
2026-12-31
Completion
2027-05-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04789057 on ClinicalTrials.gov